# 119-s-2620: REMEDY Act

119-s-2620, REMEDY Act, is a 119th Congress bill sponsored by Sen. Durbin, Richard J. [D-IL] (D-IL); status introduced; PRIA reads it as touching household money (as of 2026-07-25).

- Canonical: https://policyrisk.com/legislation/119-s-2620
- As of: 2026-07-25
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Bill: 119-s-2620
- Congress: 119
- Title: REMEDY Act
- Status: introduced
- Introduced: 2025-07-31
- Sponsor: Sen. Durbin, Richard J. [D-IL] (D-IL)
- Cosponsors: 1
- Policy area: Health
- Touches household money: yes
- Last recorded action: 2026-07-25

## Summary

**Requires brand drug sponsors to pick one binding "covered patent" for each newly approved drug.** This bill would restructure the FDA's abbreviated new drug application (ANDA) patent-certification rules and limit which patents can trigger the 30-month stay and patent suits. - Brand-name sponsors: would designate a single "covered patent" for each new drug approved after enactment. That choice is binding and cannot be changed. - Generic applicants: for post-enactment drugs they could be sued only over the chosen covered patent. For drugs approved before enactment, infringement actions can still target any certified patent submitted before the ANDA filing date. - Process and courts: the bill would clarify and align timing and scope language across approval provisions, replacing references to "the patent" with "the patent or the covered patent" to make infringement timing and the 30-month stay consistent.

## Cosponsors (1)

- Sen. Cassidy, Bill [R-LA] (R-LA), 2025-07-31T00:00:00.000Z

## Provisions PRIA read

- Existing patent rules kept for older drugs: cost, medium. If enacted, drugs approved before the law would keep the current rules. That means a patent lawsuit could be brought for any patent that was the subject of the certification and for which information was submitted before the ANDA filing date. The bill would also change statutory wording so timing t…
- One chosen patent for new drugs: mixed, medium. If enacted, drug sponsors would have to pick one "covered patent" when they first file patent information for a newly approved drug. That choice would be binding and could not be changed. For drugs approved on or after enactment, lawsuits tied to an ANDA filing could be brought only on the selected…

## Related bills

- 119-s-4744: Take Care of America’s Veterans Act
- 119-s-5071: Children's Safe Welcome Act of 2026
- 119-s-1748: Kids Online Safety Act
- 119-s-3257: John A. Hauser Mental Health in Aviation Act
- 119-s-3597: National Quantum Initiative Reauthorization Act of 2026
- 119-s-4504: Full-Service Community School Expansion Act of 2026

## Sources
- [119-s-2620 on Congress.gov](https://www.congress.gov/bill/119th-congress/senate-bill/2620)

## Related
- [119-s-4744: Take Care of America’s Veterans Act](https://policyrisk.com/legislation/119-s-4744)
- [119-s-5071: Children's Safe Welcome Act of 2026](https://policyrisk.com/legislation/119-s-5071)
- [119-s-1748: Kids Online Safety Act](https://policyrisk.com/legislation/119-s-1748)
- [119-s-3257: John A. Hauser Mental Health in Aviation Act](https://policyrisk.com/legislation/119-s-3257)
- [119-s-3597: National Quantum Initiative Reauthorization Act of 2026](https://policyrisk.com/legislation/119-s-3597)
- [119-s-4504: Full-Service Community School Expansion Act of 2026](https://policyrisk.com/legislation/119-s-4504)
- [All bills in Congress](https://policyrisk.com/legislation)

Source: PRIA, https://policyrisk.com/legislation/119-s-2620 (as of 2026-07-25).